• The Oncology Institute raised full-year 2026 revenue guidance to $650-$670 million from $630-$650 million.
• Gross profit forecast increased to $105-$110 million from $97-$107 million.
• Adjusted EBITDA outlook narrowed to $2-$7 million from $0-$9 million.
• Free cash flow guidance held at $5-$15 million.
• Update follows Q2 revenue of $161.3 million, gross profit of $27.2 million, net loss of $9.8 million, adjusted EBITDA of USD 0.23 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Oncology Institute Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001079973-26-001006), on August 06, 2026, and is solely responsible for the information contained therein.